Ana Oaknin Archives

The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data…

ESMO Congress 2022: results of two VHIO-led studies evidence the promise of immunotherapy in advanced cervical cancer

Results of long-term survival analysis of the phase III EMPOWER-Cervical 1 multicenter clinical trial show that immune checkpoint inhibitor cemiplimab…

ESMO Clinical Practice Guideline: consensus recommendations & next directions in the treatment and follow-up of endometrial cancer

Now published in the European Society for Medical Oncology’s (ESMO) flagship journal, Annals of Oncology, ESMO’s Clinical Practice Guideline for…

Under the spotlight: Nature Reviews Disease Primers illuminates the complexities of endometrial cancer & updates on recent advancements, emerging trends and therapeutic opportunities

Published last week in Nature Reviews Disease Primers, a comprehensive review* focused on endometrial cancer (EC) updates on the epidemiology,…

Cemiplimab steps up as the first immune-based therapy to improve overall survival in patients with recurrent and/or metastatic cervical cancer

Barcelona, May 12, 2021- Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death…

Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO’s Vision 2025

In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…

World Cancer Day 2021: saluting the strength of the cancer community through the COVID-19 pandemic

Thursday, February 04 2021, not only celebrates World Cancer Day’s 21st birthday but also the final year of its ‘I…